Skip to content

4576.T

D.Western Therapeutics Institute, Inc.

グロース · 医薬品 · 医薬品 · JP

JPY 85.00
−1.16%
Ask drillr

Year over year

Reported trailing growth

Revenue
-17.8%
EBITDA
EBIT
+48.8%
EPS
+63.8%
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
+3.4%
EBITDA
EPS
-14.4%

Three-year CAGR

Revenue
-4.8%
EBITDA
+50.7%
EBIT
+48.8%
Net income
+51.0%
EPS
+64.1%
Free cash flow
+62.1%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026